Publications by authors named "Bayda Bahur"
Article Synopsis
- Therapeutic drug monitoring (TDM) for anti-tumor necrosis factor (anti-TNF) treatments in inflammatory bowel disease (IBD) can improve treatment outcomes and manage failures more cost-effectively, but slow lab results hinder its widespread use.
- *To address this issue, point-of-care technology tests (POCTs) offer rapid results at the patient's location, allowing for faster treatment decisions compared to the current standard method, the ELISA assay.
- *This study evaluated a new POCT method (ProciseDx) against the standard ELISA method for measuring drug levels in IBD patients and found a strong correlation between the two, suggesting the POCT could be a practical alternative in clinical settings.*
The original version of the article unfortunately contained a couple of errors. In 'methods' section, in 'Outcomes' subsection, the sentence 'Endoscopic remission was defined as an SESCD ≤ 2 in patients with CD and an EMS ≤ 2 in UC patients while off corticosteroids.'
View Article and Find Full Text PDFBackground And Aims: Vedolizumab is an anti-α4β7 biologic approved for ulcerative colitis [UC] and Crohn's disease [CD]. We aimed to examine the association of maintenance vedolizumab concentrations with remission.
Methods: We performed a cross-sectional multi-centre study of inflammatory bowel disease [IBD] patients on maintenance vedolizumab.
Background: The aim of this study was to assess the relationship of serum vedolizumab concentrations (SVC) during induction and endoscopic remission in patients with inflammatory bowel diseases (IBD) after 52 weeks of therapy with vedolizumab. We also sought to assess the incidence of antibody to vedolizumab (ATV) formation, the effect of ATV on drug pharmacokinetics and efficacy, and identify variables associated with SVC through the first 30 weeks of treatment.
Methods: This is a prospective cohort study of patients with active IBD initiating standard therapy with vedolizumab.
Background: Chronic rejection is a major cause of graft loss in kidney transplant recipients. Nonadherence to drug therapy is a well-recognized cause of chronic rejection leading to long-term graft dysfunction and failure for transplant recipients. Immunosuppressive medications with short half-lives that require frequent dosing, such as tacrolimus, complicate transplant regimens and may increase noncompliance.
View Article and Find Full Text PDF